Govindan R, et al. Phase 1 study of safety, tolerability, PK and efficacy of AMG 510, a novel KRAS G12Cinhibitor, evaluated in NSCLC. Abstract OA02.02. WCLC 2019, 7-10 september, Barcelona, Spanje.
Ceritinib versus chemotherapie bij gevorderd ALK-positief NSCLC: ASCEND-4
mrt 2017 | Longoncologie